Intellia Therapeutics (NTLA) Gains from Investment Securities (2022 - 2023)

Intellia Therapeutics' (NTLA) quarterly Gains from Investment Securities came in at $100000.0 in Q1 2023, down 76.25% year-on-year from $421000.0 in Q1 2022, and down 98.16% on a QoQ basis from $5.4 million in Q4 2022.

Intellia Therapeutics (NTLA) Gains from Investment Securities (2022 - 2023) Analysis & Trends

Intellia Therapeutics (NTLA) has 2 years of Gains from Investment Securities data on file, last reported at $100000.0 in Q1 2023.

  • On a quarterly basis, Gains from Investment Securities fell 76.25% year-over-year to $100000.0 in Q1 2023; TTM through Dec 2023 was $100000.0, a 99.26% decrease from a year earlier, with the FY2023 full-year figure at $100000.0, down 99.26% from the prior year.
  • Gains from Investment Securities for Q1 2023 stood at $100000.0, down from $5.4 million in the prior quarter.
  • Over the last five years, Gains from Investment Securities for NTLA reached as high as $7.8 million in Q3 2022 and fell as low as -$172000.0 in Q2 2022.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 Intellia Therapeutics 1.27 Bn 1.27 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2023 100,000.00
Mar 31, 2023 100,000.00
Dec 31, 2022 5.43 Mn
Dec 31, 2022 5.43 Mn
Sep 30, 2022 7.81 Mn
Sep 30, 2022 7.81 Mn
Jun 30, 2022 -172,000.00
Jun 30, 2022 -172,000.00
Mar 31, 2022 421,000.00
Mar 31, 2022 421,000.00